 | | Vol. 14.10 – 17 March, 2022 |
| |
|
|
| Investigators demonstrated that the breast cancer stem cell secretome autonomously compressed the stem cell population.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The mechanisms underlying MYC deubiquitination in breast cancer were not well defined. Researchers reported that OTUB1 was responsible for MYC deubiquitination.
[Cell Death & Differentiation] |
|
|
|
| Investigators illustrated that HIF-2α induced stemness in breast cancers under hypoxia through the SOD2-mtROS-PDI/GRP78-UPRER pathway, linking mitochondrial metabolic state to endoplasmic reticulum response via mitochondrial reactive oxygen species (mtROS) level.
[Cell Death & Differentiation] |
|
|
|
| Scientists found that doxorubicin treatment significantly induced RNA N6-methyladenosine (m6A) methylation in breast cancer cells in both a dose- and time-dependent manner.
[Molecular Therapy] |
|
|
|
| Knockdown of salt-inducible kinase 2 (SIK2) expression reduced the proportion of breast cancer (BC) stem cells and the tumor initiation of BC cells.
[Oncogene] |
|
|
|
| Using organotypic models from mouse invasive ductal and invasive lobular breast cancers, researchers showed that increased collagen bundling in 3D induced a generic increase in breast cancer invasion that was independent of migration mode.
[Oncogene] |
|
|
|
| MiRNAs that targeted ADP-ribosylation factor 6 (ARF6) were predicted and selected in high metastatic breast cancer cells treated with C–C motif chemokine ligand 18 (CCL18).
[Molecular Therapy Oncolytics] |
|
|
|
| YTHDF1 facilitated S-phase entry, DNA replication and DNA damage repair, and accordingly YTHDF1 knockdown sensitized breast cancer cells to Adriamycin and Cisplatin as well as Olaparib, a poly ADP ribose polymerase inhibitor.
[Cell Death & Disease] |
|
|
|
| Investigators found that the zinc complex of 3,5-di-tert-butyl salicylate compound inhibited viability, invasion, and migration and induced apoptosis in TNBC 4T1 cells.
[Scientific Reports] |
|
|
|
| Circular RNA-trefoil factor 1 (circ-TFF1) and interleukin-1 receptor-associated kinase 1 (IRAK1) were highly expressed in breast cancer tissues and cells. While the silencing of circ-TFF1 reduced the proliferation, migration, invasion and tube formation, it increased the apoptosis of MDA-MB-361 and SK-Br-3 cells.
[Biochemical Genetics] |
|
|
|
|
| The authors cover the current biological understanding of the interleukin-6 (IL-6) signaling pathway and its impact on breast cancer metastasis, as well as therapeutic interventions that target components of the IL-6 pathway.
[Frontiers in Oncology] |
|
|
|
|
| AstraZeneca and Merck announced additional positive results from the Phase III OlympiA trial, where LYNPARZA demonstrated a statistically significant improvement in overall survival for the treatment of high-risk early breast cancer.
[Merck] |
|
|
|
|
|
|
|
| | Case Western Reserve University – Cleveland, OH, United States |
|
|
|
| | Institute of Cancer Research – London, England, United Kingdom |
|
|
|
| | Diagnostisk Center, Rigshospitalet – Copenhagen, Denmark |
|
|
|
| | Institute of Cancer Research – London, England, United Kingdom |
|
|
|
| | German Cancer Research Center in the Helmholtz Association – Heidelberg, German |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
